Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1126/scitranslmed.abh2624 http://scihub22266oqcxt.onion/10.1126/scitranslmed.abh2624 34429372!8601717!34429372     free     free     free Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Sci+Transl+Med 2021 ; 13 (612): eabh2624 Nephropedia Template TP {{tp|p=34429372|t=2021. Type I interferon autoantibodies are associated with systemic immune alterations in patients with COVID-19 |pdf=|usr=}}{{34429372}} gab.com Text Type I interferon autoantibodies are associated with systemic immune alterations in patients with COVID-19 JO: Sci Transl Med http://www.kidney.de/pget.php?&tw=1&pmid=34429372 #FOAvip Neutralizing autoantibodies against type I interferons (IFNs) have been found in some patients with critical coronavirus disease 2019 (COVID-19), the disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, the prevalence of these antibodies, their longitudinal dynamics across the disease severity scale, and their functional effects on circulating leukocytes remain unknown. Here, in 284 patients with COVID-19, we found type I IFN-specific autoantibodies in peripheral blood samples from 19% of patients with critical disease and 6% of patients with severe disease. We found no type I IFN autoantibodies in individuals with moderate disease. Longitudinal profiling of over 600,000 peripheral blood mononuclear cells using multiplexed single-cell epitope and transcriptome sequencing from 54 patients with COVID-19 and 26 non-COVID-19 controls revealed a lack of type I IFN-stimulated gene (ISG-I) responses in myeloid cells from patients with critical disease. This was especially evident in dendritic cell populations isolated from patients with critical disease producing type I IFN-specific autoantibodies. Moreover, we found elevated expression of the inhibitory receptor leukocyte-associated immunoglobulin-like receptor 1 (LAIR1) on the surface of monocytes isolated from patients with critical disease early in the disease course. LAIR1 expression is inversely correlated with ISG-I expression response in patients with COVID-19 but is not expressed in healthy controls. The deficient ISG-I response observed in patients with critical COVID-19 with and without type I IFN-specific autoantibodies supports a unifying model for disease pathogenesis involving ISG-I suppression through convergent mechanisms. Twit Text FOAVip Type I interferon autoantibodies are associated with systemic immune alterations in patients with COVID-19 ????Sci Transl Med http://www.kidney.de/pget.php?&tw=1&pmid=34429372 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34429372 #FOAvip English Wikipedia <ref>{{Cite pmid|34429372}}</ref> Type I interferon autoantibodies are associated with systemic immune alterations in patients with COVID-19 #MMPMID34429372 van der Wijst MGP; Vazquez SE; Hartoularos GC; Bastard P; Grant T; Bueno R; Lee DS; Greenland JR; Sun Y; Perez R; Ogorodnikov A; Ward A; Mann SA; Lynch KL; Yun C; Havlir DV; Chamie G; Marquez C; Greenhouse B; Lionakis MS; Norris PJ; Dumont LJ; Kelly K; Zhang P; Zhang Q; Gervais A; Le Voyer T; Whatley A; Si Y; Byrne A; Combes AJ; Rao AA; Song YS; Fragiadakis GK; Kangelaris K; Calfee CS; Erle DJ; Hendrickson C; Krummel MF; Woodruff PG; Langelier CR; Casanova JL; Derisi JL; Anderson MS; Ye CJ Sci Transl Med 2021[Sep]; 13 (612): eabh2624 PMID34429372show ga Neutralizing autoantibodies against type I interferons (IFNs) have been found in some patients with critical coronavirus disease 2019 (COVID-19), the disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, the prevalence of these antibodies, their longitudinal dynamics across the disease severity scale, and their functional effects on circulating leukocytes remain unknown. Here, in 284 patients with COVID-19, we found type I IFN-specific autoantibodies in peripheral blood samples from 19% of patients with critical disease and 6% of patients with severe disease. We found no type I IFN autoantibodies in individuals with moderate disease. Longitudinal profiling of over 600,000 peripheral blood mononuclear cells using multiplexed single-cell epitope and transcriptome sequencing from 54 patients with COVID-19 and 26 non-COVID-19 controls revealed a lack of type I IFN-stimulated gene (ISG-I) responses in myeloid cells from patients with critical disease. This was especially evident in dendritic cell populations isolated from patients with critical disease producing type I IFN-specific autoantibodies. Moreover, we found elevated expression of the inhibitory receptor leukocyte-associated immunoglobulin-like receptor 1 (LAIR1) on the surface of monocytes isolated from patients with critical disease early in the disease course. LAIR1 expression is inversely correlated with ISG-I expression response in patients with COVID-19 but is not expressed in healthy controls. The deficient ISG-I response observed in patients with critical COVID-19 with and without type I IFN-specific autoantibodies supports a unifying model for disease pathogenesis involving ISG-I suppression through convergent mechanisms. |*Autoantibodies/immunology[MESH] |*COVID-19/immunology[MESH] |*Interferon Type I/immunology[MESH]Type I interferon autoantibodies are associated with systemic immune a(epmc).pdf DeepDyve Pubget Overpricing